Shares of Amsurg Corp. (NYSE:EVHC) have been assigned a consensus rating of “Buy” from the eighteen research firms that are currently covering the stock. Five research analysts have rated the stock with a hold rating and thirteen have issued a buy rating on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $37.57.
A number of research analysts recently issued reports on the company. Jefferies Group set a $32.00 price target on Amsurg Corp. and gave the company a “buy” rating in a report on Sunday, December 4th. Goldman Sachs Group Inc. assumed coverage on Amsurg Corp. in a report on Friday, December 9th. They set a “buy” rating on the stock. Zacks Investment Research upgraded Amsurg Corp. from a “sell” rating to a “hold” rating in a report on Tuesday, November 1st. Canaccord Genuity restated a “buy” rating on shares of Amsurg Corp. in a report on Friday, December 9th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $31.00 price target on shares of Amsurg Corp. in a report on Thursday, September 8th.
COPYRIGHT VIOLATION NOTICE: This news story was first published by American Market News and is owned by of American Market News. If you are accessing this news story on another website, it was stolen and republished in violation of US & international copyright and trademark laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2016/12/14/amsurg-corp-evhc-receives-consensus-recommendation-of-buy-from-analysts.html.
Amsurg Corp. (NYSE:EVHC) last released its quarterly earnings data on Tuesday, November 1st. The company reported $0.36 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.36. Amsurg Corp. had a return on equity of 8.05% and a net margin of 6.06%. The firm had revenue of $1.64 billion for the quarter, compared to the consensus estimate of $1.67 billion. During the same quarter in the previous year, the business earned $0.30 earnings per share. The company’s quarterly revenue was up 19.8% on a year-over-year basis. On average, analysts anticipate that Amsurg Corp. will post $1.40 earnings per share for the current fiscal year.
Hedge funds have recently modified their holdings of the company. IBM Retirement Fund boosted its position in Amsurg Corp. by 0.4% in the second quarter. IBM Retirement Fund now owns 18,798 shares of the company’s stock valued at $477,000 after buying an additional 68 shares during the period. Sumitomo Mitsui Asset Management Company LTD boosted its position in Amsurg Corp. by 1.3% in the second quarter. Sumitomo Mitsui Asset Management Company LTD now owns 12,559 shares of the company’s stock valued at $318,000 after buying an additional 162 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its position in Amsurg Corp. by 1.5% in the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 26,872 shares of the company’s stock valued at $598,000 after buying an additional 402 shares during the period. Pacer Advisors Inc. boosted its position in Amsurg Corp. by 7.4% in the third quarter. Pacer Advisors Inc. now owns 7,045 shares of the company’s stock valued at $157,000 after buying an additional 484 shares during the period. Finally, Nordea Investment Management AB boosted its position in Amsurg Corp. by 9.8% in the second quarter. Nordea Investment Management AB now owns 5,457 shares of the company’s stock valued at $138,000 after buying an additional 488 shares during the period.
Amsurg Corp. Company Profile
Envision Healthcare Holdings, Inc, formerly CDRT Holding Corporation, is a holding company. The Company, through its subsidiary, provides physician-led medical services in the United States. It operates in two segments: EmCare Holdings, Inc (EmCare) and American Medical Response, Inc (AMR). Its EmCare segment is a provider of integrated facility-based and post-acute care physician services to healthcare facilities in the United States.
